Medivation (MDVN) Preclinical Excitement Seems To Be Bearing Fruit - Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
AstraZeneca (AZN) Considering Offer for Medivation (MDVN) - Times
April 18, 2016 7:14 AM EDTAstraZeneca (NYSE: AZN) has held internal talks and is looking very closely at an offer for Medivation (NASDAQ: MDVN), according to The Times.
Medivation (MDVN) Taps Session High
April 15, 2016 9:55 AM EDTMedivation (NASDAQ: MDVN) advanced Friday morning, rising 6%.
Leerink Highlights Top 10 Biopharma Stocks for Partnerships & Acquisitions
April 14, 2016 12:07 PM EDTIn addition to naming Acadia Pharma (NASDAQ: ACAD) one of his top partnership and acquisition (P&A) targets, as noted earlier, Leerink analyst Joseph Schwartz listed 9 other stocks on his Top 10 list. Below is a run-down of the others:
Akorn, Inc. (NASDAQ: AKRX) (Market Perform)
Rationale for P&A: "AKRX operates in generic segments with higher barriers... More
